| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/19/2000 | EP1020464A1 Paroxetine methansulfonate |
| 07/19/2000 | EP1020463A1 Paroxetine methanesulfonate |
| 07/19/2000 | EP1020452A1 Benzimidazole derivatives |
| 07/19/2000 | EP1020439A1 Cetp activity inhibitors |
| 07/19/2000 | EP1020192A2 Composition against cellulitis |
| 07/19/2000 | EP1020191A1 Medicaments for hypolipidemic and hypoglycemic conditions |
| 07/19/2000 | EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 07/19/2000 | EP1019412A1 Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht 1d? receptor antagonists |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019408A1 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- |
| 07/19/2000 | EP1019402A1 Polymorphic forms of a growth hormone secretagogue |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019386A1 Reverse hydroxamate derivatives as metalloprotease inhibitors |
| 07/19/2000 | EP1019378A1 Hypoglycemic and hypolipidemic compounds |
| 07/19/2000 | EP1019364A2 Inhibitors of protein tyrosine phosphatase |
| 07/19/2000 | EP1019092A1 Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| 07/19/2000 | EP1019089A2 Long-acting drugs and pharmaceutical compositions comprising them |
| 07/19/2000 | EP1019082A1 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 07/19/2000 | EP1019077A1 Novel exendin agonist compounds |
| 07/19/2000 | EP1019073A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 07/19/2000 | EP1019062A1 Osteoblast-specific mitogens and drugs containing such compounds |
| 07/19/2000 | EP1019057A1 A method of preventing or treating estrogen-dependent diseases and disorders |
| 07/19/2000 | EP1019049A1 Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (niddm) using specific retinoid compounds |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP1019010A1 Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 07/19/2000 | EP0760819B1 Tricyclic dicarbonyl derivatives |
| 07/19/2000 | EP0674626B1 Selective aromatase inhibiting compounds |
| 07/19/2000 | CN1260789A Heterocyclic compounds, method for preparing and medicine compositions containing same |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260774A Method for producing medicines containing HMG-CoA-reductase inhibitors |
| 07/19/2000 | CN1260719A Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 07/19/2000 | CN1260716A Treatment of diabetes with thiazolidinedione and metformin |
| 07/19/2000 | CN1260715A Treatment of diabetes with rosiglitazone and insulin |
| 07/19/2000 | CN1260345A Hydrazide compound, its preparing method and medicine compositions thereof |
| 07/19/2000 | CN1260204A Medicament for treating diabetes and its preparation method |
| 07/19/2000 | CN1260181A Salmon spawn oleoginous capsule with high-nutrient and blood-lipid depression preparation method |
| 07/19/2000 | CN1054532C Medicine for treating diabetes |
| 07/19/2000 | CN1054525C Medicinal composition for treating dibetes |
| 07/19/2000 | CN1054524C Medicinal composition for treating diabetes |
| 07/18/2000 | US6090944 Alkanoic acid derivatives as αv integrin receptor antagonists |
| 07/18/2000 | US6090833 Polycyclic dihydrothiazoles, their preparation, and use as pharmaceuticals |
| 07/18/2000 | US6090583 Expression system in compatible host cell of a polynucleotide which produces a metalloprotease; diagnosis and treatment of asthma, disorders of leukotriene metabolism; anticarcinogenic agents; antiinflammatory/antidiabetic/antiarthritic agents |
| 07/18/2000 | US6090410 Dry mix formulation for bisphosphonic acids |
| 07/18/2000 | US6090382 Human antibodies that bind human TNFα |
| 07/18/2000 | CA2008616C Aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
| 07/15/2000 | CA2296134A1 Use of at least one extract of at least one non-photosynthetic filamentous bacterium as a slimming agent |
| 07/13/2000 | WO2000040733A1 Human cyclic nucleotide pdes |
| 07/13/2000 | WO2000040725A1 Screening method |
| 07/13/2000 | WO2000040722A2 Insulin-synthesis genes |
| 07/13/2000 | WO2000040716A2 Soluble receptor br43x2 and methods of using them for therapy |
| 07/13/2000 | WO2000040714A2 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | WO2000040705A2 Human desaturase gene and uses thereof |
| 07/13/2000 | WO2000040693A2 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/13/2000 | WO2000040615A2 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS |
| 07/13/2000 | WO2000040614A2 Characterization of the soc/crac calcium channel protein family |
| 07/13/2000 | WO2000040613A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040612A1 Insulin-like growth factor (igf) i mutant variants |
| 07/13/2000 | WO2000040597A1 Method and composition for angiogenesis inhibition |
| 07/13/2000 | WO2000040592A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | WO2000040584A2 Process for preparing n6-substituted deaza-adenosine derivatives |
| 07/13/2000 | WO2000040569A1 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040560A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 07/13/2000 | WO2000040247A1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/13/2000 | WO2000040243A1 Novel compounds |
| 07/13/2000 | WO2000040225A2 Inhibition of tnf activity |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000024897B1 Cell surface molecule-induced macrophage activation |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000023063A3 Methods for inhibiting diabetic complications |
| 07/13/2000 | WO2000021986A3 Matrix-remodeling genes |
| 07/13/2000 | WO2000021927A3 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000015174A3 Bioflavonoid as blood glucose level lowering agent |
| 07/13/2000 | WO2000010958A9 Vitamin d3 mimics |
| 07/13/2000 | WO2000009666A9 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
| 07/13/2000 | WO2000006534A9 Compounds and compositions for delivering active agents |
| 07/13/2000 | DE19845405C2 Arylsubstituierte Propanolaminderivate und deren Verwendung Aryl-substituted Propanolaminderivate and their use |
| 07/13/2000 | CA2753331A1 Soluble receptor br43x2 and methods of using |
| 07/13/2000 | CA2360396A1 Characterization of a calcium channel family |
| 07/13/2000 | CA2358962A1 Process for preparing n6-substituted deaza-adenosine derivatives |
| 07/13/2000 | CA2358543A1 Human desaturase gene and uses thereof |
| 07/13/2000 | CA2357986A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof |
| 07/13/2000 | CA2357950A1 Therapeutic phosphodiesterase inhibitors |
| 07/13/2000 | CA2357677A1 Insulin-synthesis genes |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356412A1 Screening method |
| 07/13/2000 | CA2356401A1 Expression and export of anti-obesity proteins as fc fusion proteins |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2354638A1 Expression of secreted human alpha-fetoprotein in transgenic animals |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1017697A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 07/12/2000 | EP1017693A1 Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them |
| 07/12/2000 | EP1017692A1 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein |
| 07/12/2000 | EP1017677A1 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein |
| 07/12/2000 | EP1017672A1 New npy antagonists |
| 07/12/2000 | EP1017658A1 Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia |
| 07/12/2000 | EP1017423A1 Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2000 | EP1017416A1 Treatment of cardiomyopathy |
| 07/12/2000 | EP1017414A1 Therapeutic method for management of diabetes mellitus |
| 07/12/2000 | EP1017408A1 Use of gastrointestinal lipase inhibitors |